Novavax Inc. [NASDAQ: NVAX] closed the trading session at $8.21 on 09/01/23. The day’s price range saw the stock hit a low of $8.02, while the highest price level was $8.465. The company report on August 22, 2023 at 7:00 AM that Novavax’s Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6.
Novavax’s 2023-2024 season COVID vaccine candidate induced neutralizing responses to emerging subvariants EG.5.1 and XBB.1.16.6 in addition to XBB.1.5, XBB.1.16 and XBB.2.3.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Upon regulatory approval, Novavax’s COVID vaccine would be the only protein-based non-mRNA vaccine option available in key markets for the fall season.
The stocks have a year to date performance of -20.14 percent and weekly performance of 1.99 percent. The stock has been moved at 6.76 percent over the last six months. The stock has performed -0.24 percent around the most recent 30 days and changed 7.74 percent over the most recent 3-months.
If compared to the average trading volume of 7.28M shares, NVAX reached to a volume of 7978620 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Novavax Inc. [NVAX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVAX shares is $20.60 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVAX stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
B. Riley Securities have made an estimate for Novavax Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 09, 2023.
The Average True Range (ATR) for Novavax Inc. is set at 0.68, with the Price to Sales ratio for NVAX stock in the period of the last 12 months amounting to 0.47.
NVAX stock trade performance evaluation
Novavax Inc. [NVAX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.99. With this latest performance, NVAX shares dropped by -0.24% in over the last four-week period, additionally plugging by 6.76% over the last 6 months – not to mention a drop of -75.15% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVAX stock in for the last two-week period is set at 52.01, with the RSI for the last a single of trading hit 52.34, and the three-weeks RSI is set at 51.64 for Novavax Inc. [NVAX]. The present Moving Average for the last 50 days of trading for this stock 7.97, while it was recorded at 8.24 for the last single week of trading, and 9.50 for the last 200 days.
Novavax Inc. [NVAX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Novavax Inc. [NVAX] shares currently have an operating margin of -32.53 and a Gross Margin at +54.46. Novavax Inc.’s Net Margin is presently recorded at -33.20.
Reflecting on the efficiency of the workforce at the company, Novavax Inc. [NVAX] managed to generate an average of -$330,291 per employee. Receivables Turnover for the company is 7.38 with a Total Asset Turnover recorded at a value of 0.82.Novavax Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 0.70.
Novavax Inc. [NVAX]: Institutional Ownership
The top three institutional holders of NVAX stocks are: VANGUARD GROUP INC with ownership of 1.31 billion shares, which is approximately 8.2089%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $170.67 trillion in NVAX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $150.98 trillion in NVAX stock with ownership which is approximately 5.7381%.
